Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

31.80 -0.23 (-0.73%)
Streaming Delayed Price Updated: 1:17 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 403,365
Open 32.00
Bid (Size) 31.77 (3)
Ask (Size) 31.84 (2)
Prev. Close 32.04
Today's Range 31.39 - 32.63
52wk Range 16.95 - 49.50
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Performance

YTD
+16.03%
+16.03%
1 Month
+37.98%
+37.98%
3 Month
+44.24%
+44.24%
6 Month
+12.42%
+12.42%
1 Year
+3.03%
+3.03%

More News

Read More
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Expert Ratings For Beam Therapeutics
Via Benzinga
Why Is Conn’s (CONN) Stock Down 36% Today?
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
Via InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
Via InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
Via InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
From Beam Therapeutics
Via GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Via InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.